carbamates has been researched along with Seizures in 111 studies
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to evaluate the efficacy and safety of adjunctive retigabine/ezogabine (RTG/EZG) therapy in Asian adults with partial-onset seizures." | 9.22 | Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study. ( Kwan, P; Lim, KS; Lotay, N; White, R, 2016) |
| " Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA)." | 9.20 | Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. ( Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015) |
| " Oxotremorine is a cholinergic agonist known to induce acute hypothermia." | 7.74 | Oxotremorine-induced hypothermia as a method for evaluating long-term neuronal changes following poisoning by cholinesterase inhibitors in rats. ( Grauer, E; Levy, A, 2007) |
| "reduction in 28-day total partial seizure frequency of ≥50%) than placebo during both the 12-week maintenance period and the entire 16- or 18-week double-blind phase (i." | 6.47 | Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. ( Deeks, ED, 2011) |
| "There was no apparent change of the seizure initiation pattern when kainic acid was coadministrated with AM404, URB597 or AM251." | 5.42 | Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs. ( Aliev, R; Kitchigina, V; Shubina, L, 2015) |
| "Brivaracetam (BRV), cenobamate (CNB), eslicarbazepine acetate (ESL), lacosamide (LCM) and perampanel (PER) are antiseizure medications (ASMs) approved for adjunctive treatment of focal-onset seizures." | 5.22 | Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis. ( Brigo, F; Del Giovane, C; Lattanzi, S; Russo, E; Silvestrini, M; Striano, P; Trinka, E; Zaccara, G, 2022) |
| "The purpose of this study was to evaluate the efficacy and safety of adjunctive retigabine/ezogabine (RTG/EZG) therapy in Asian adults with partial-onset seizures." | 5.22 | Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study. ( Kwan, P; Lim, KS; Lotay, N; White, R, 2016) |
| " Adults with partial-onset seizures must have been taking either carbamazepine/oxcarbazepine (CBZ/OXC), lamotrigine (LTG), levetiracetam (LEV), or valproic acid (VPA)." | 5.20 | Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures. ( Brandt, C; Daniluk, J; DeRossett, S; Edwards, S; Lerche, H; Lotay, N, 2015) |
| " Food and Drug Administration approved Potiga (ezogabine) as an add-on medication for the treatment of seizures in adults, and it is being developed by Valeant Pharmaceuticals." | 4.88 | ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine). ( Hopkins, CR, 2012) |
| "To isobolographically determine the types of interactions that occur between retigabine and lacosamide (LCM; two third-generation antiepileptic drugs) with respect to their anticonvulsant activity and acute adverse effects (sedation) in the maximal electroshock-induced seizures (MES) and chimney test (motor performance) in adult male Swiss mice." | 3.88 | Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis. ( Adamczuk, P; Czuczwar, SJ; Florek-Luszczki, M; Kondrat-Wrobel, MW; Luszczki, JJ; Miziak, B; Wroblewska-Luczka, P; Zagaja, M; Zaluska, K, 2018) |
| "To assess interactions between retigabine and levetiracetam in suppressing maximal electroshock-induced tonic seizures in Albino Swiss mice, type II isobolographic analysis was used." | 3.81 | Synergistic Interaction of Retigabine with Levetiracetam in the Mouse Maximal Electroshock-Induced Seizure Model: A Type II Isobolographic Analysis. ( Czuczwar, SJ; Florek-Luszczki, M; Luszczki, JJ; Miziak, B; Zagaja, M, 2015) |
| " This compound was effective in delaying onset of PTZ-evoked seizures at the dose of 5mg/kg in kindled animals and significantly reduced oxidative stress better than standard drug phenobarbital (PB)." | 3.81 | Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents. ( Kumari, S; Mishra, CB; Tiwari, M, 2015) |
| " The effects of systemic injection of H3R ligands 1-13 on MES-induced and PTZ-kindled seizures were screened and evaluated against the reference antiepileptic drug (AED) Phenytoin (PHT) and the standard histamine H3R inverse agonist/antagonist Thioperamide (THP) to determine their potential as new antiepileptic drugs." | 3.79 | Anticonvulsant properties of histamine H3 receptor ligands belonging to N-substituted carbamates of imidazopropanol. ( Adem, A; Kieć-Kononowicz, K; Sadek, B; Shafiullah, M; Shehab, S; Subramanian, D; Więcek, M, 2013) |
| "A novel class of 19 carbamates was synthesized, and their anticonvulsant activity was comparatively evaluated in the rat maximal electroshock (MES) and subcutaneous metrazol (scMet) seizure tests and pilocarpine-induced status epilepticus (SE) model." | 3.78 | Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. ( Bialer, M; Hen, N; Yagen, B, 2012) |
| " In the rat Li-pilocarpine status epilepticus model, CYM2503, injected intraperitoneally, increased the latency to first electrographic seizure and the latency to first stage 3 behavioral seizure, decreased the latency to the establishment of status epilepticus, and dramatically decreased the mortality." | 3.76 | GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models. ( Baldwin, R; Bartfai, T; Chang, J; Liu, T; Lu, X; Roberts, E; Sanchez-Alavez, M; Wasterlain, CG; Wu, S; Xia, F, 2010) |
| " Carisbamate reduced the frequency of spontaneous motor seizures in a dose-dependent manner, and was more effective than topiramate at reducing seizures in rats with kainate-induced epilepsy." | 3.74 | A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy. ( Dudek, FE; Grabenstatter, HL, 2008) |
| " Oxotremorine is a cholinergic agonist known to induce acute hypothermia." | 3.74 | Oxotremorine-induced hypothermia as a method for evaluating long-term neuronal changes following poisoning by cholinesterase inhibitors in rats. ( Grauer, E; Levy, A, 2007) |
| " This post hoc analysis reports onset of efficacy and characterizes time to onset, duration, and severity of the most common treatment-emergent adverse events (TEAEs) during cenobamate titration." | 3.11 | Onset of efficacy and adverse events during Cenobamate titration period. ( Ben-Menachem, E; Brandt, C; García Morales, I; Rosenfeld, WE; Santamarina, E; Serratosa, JM; Steinhoff, BJ, 2022) |
| "Patients with uncontrolled focal seizures taking stable doses of 1-3 antiseizure medications were administered increasing doses of cenobamate (12." | 3.11 | Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: Adjunctive cenobamate dose and seizure reduction by baseline seizure frequency. ( Aboumatar, S; Biton, V; Ferrari, L; Rosenfeld, WE; Wechsler, R, 2022) |
| " Increased dosage of cenobamate across 150-400 mg/day range was significantly associated with higher responder rates (p < 0." | 3.01 | Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment. ( Coe, P; Elizebath, R; Gutierrez, EG; Krauss, GL; Yang, J; Zhang, E, 2021) |
| "Adults with uncontrolled focal seizures despite treatment with 1-3 antiepileptic drugs/antiseizure medications (AEDs/ASMs) were randomized 1:1:1:1 to placebo or cenobamate 100, 200, or 400 mg once daily." | 3.01 | Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study. ( Ferrari, L; Nisman, A; Rosenfeld, WE, 2021) |
| " Safety assessments included frequency of treatment-emergent adverse events (TEAEs) and serious TEAEs, TEAE severity, and TEAEs leading to discontinuation." | 3.01 | Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study. ( Chung, SS; French, JA; Kamin, M; Krauss, GL; Lee, SK; Maciejowski, M; Rosenfeld, WE; Sperling, MR, 2021) |
| "Median baseline seizure frequency was 6." | 2.94 | Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. ( Chung, SS; French, JA; Kamin, M; Kowalski, J; Krauss, GL; Lee, SK; Maciejowski, M; Mizne, S; Rosenfeld, WE; Sperling, MR, 2020) |
| "0%) discontinued, most commonly due to adverse events (n = 137) and consent withdrawn for reason other than adverse event (n = 74); 1339 patients received ≥1 treatment dose (median modal dose = 200 mg)." | 2.94 | Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. ( Aboumatar, S; Borchert, L; Gelfand, M; Halford, JJ; Kamin, M; Klein, P; Krauss, GL; Rosenfeld, WE; Sperling, MR; Vossler, DG; Wechsler, R, 2020) |
| " Safety assessments included monitoring treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)." | 2.94 | Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events. ( Boll, MC; Brickel, N; Cooper, J; Daniluk, J; De'Ath, J; Hewett, K; Joshi, K; McDonald, S; Rayner, K; Tiamkao, S; Vorobyeva, O, 2020) |
| " We calculated the risk ratio (RR) of ≥50%, ≥75% and 100% reduction in seizure frequency from baseline, as well as dropout and serious adverse events related to treatment." | 2.72 | Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis. ( Wang, C; Wang, J; Zhang, L, 2021) |
| "Epilepsy is one of the most common and disabling chronic neurological disorders." | 2.72 | The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. ( Klein, P; Löscher, W, 2021) |
| "To achieve seizure freedom in such patients with any modified ASD regimen is an exception." | 2.72 | [Cenobamate-a new perspective for epilepsy treatment]. ( Steinhoff, BJ, 2021) |
| " Chemical classification, structure, mechanism of action, pharmacokinetic data and therapeutic ranges for total and free fractions and interactions were collected." | 2.66 | New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs). ( Główka, FK; Karaźniewcz-Łada, M; Sommerfeld-Klatta, K; Zielińska-Psuja, B, 2020) |
| "The pooled estimated RR to achieve seizure freedom for the cenobamate group in comparison with placebo was 3." | 2.66 | Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis. ( Brigo, F; Del Giovane, C; Lattanzi, S; Silvestrini, M; Striano, P; Trinka, E; Zaccara, G, 2020) |
| "Although CBM displayed impressive seizure reduction in clinical trials across all seizure types, including focal aware motor, focal impaired awareness, and focal to bilateral tonic-clonic seizures, the precise mechanism(s) through which CBM exerts its broad-spectrum antiseizure effects is not known." | 2.66 | Cenobamate (XCOPRI): Can preclinical and clinical evidence provide insight into its mechanism of action? ( Campbell, A; Guignet, M; White, HS, 2020) |
| "The aim of this review was to evaluate current literature for dosing recommendations for the use of antiepileptic medications in patients receiving renal replacement therapy (RRT)." | 2.53 | Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. ( Bastin, ML; Cook, AM; Oyler, DR; Smetana, KS, 2016) |
| " It is well absorbed from the digestive system and undergoes metabolism via glucuronidation and acetylation." | 2.49 | [Retigabine - a new antiepileptic drug with a different mechanism of action]. ( Pietrzak, B; Zwierzyńska, E, 2013) |
| "reduction in 28-day total partial seizure frequency of ≥50%) than placebo during both the 12-week maintenance period and the entire 16- or 18-week double-blind phase (i." | 2.47 | Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy. ( Deeks, ED, 2011) |
| "CNS excitation and seizures, manifestations of organochlorine intoxication, can occur following ingestion or inappropriate application of the 1 per cent topical formulation of lindane used to treat scabies and lice." | 2.37 | Management of acute childhood poisonings caused by selected insecticides and herbicides. ( Mortensen, ML, 1986) |
| "Cenobamate is an antiseizure medication (ASM) approved for the treatment of partial-onset seizures in adults." | 1.91 | A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam. ( Bien, CG; Brandt, C; Elakkary, S; Hagemann, A; Klimpel, D, 2023) |
| " CNB shows 88% of oral bioavailability and is responsible for modifying the plasma concentrations of other co-administered ASMs, such as lamotrigine, carbamazepine, phenytoin, phenobarbital and the active metabolite of clobazam." | 1.72 | Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples. ( Charlier, B; Coglianese, A; Coppola, G; Dal Piaz, F; de Grazia, U; Filippelli, A; Izzo, V; Menna, P; Operto, FF, 2022) |
| "Patients with uncontrolled focal seizures despite taking stable doses of 1-3 concomitant antiseizure medications (ASMs) received increasing doses of cenobamate (12." | 1.72 | Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study. ( Abou-Khalil, B; Aboumatar, S; Klein, P; Krauss, GL; Rosenfeld, WE; Sperling, MR, 2022) |
| "Median baseline seizure frequencies/28 days were 10." | 1.72 | Efficacy of cenobamate by focal seizure subtypes: Post-hoc analysis of a phase 3, multicenter, open-label study. ( Ferrari, L; Kamin, M; Rosenfeld, WE, 2022) |
| "We measured seizure reduction, median reduction in seizure frequency, median dose, responder rate, and treatment-emergent adverse events." | 1.72 | Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study. ( Karkare, S; Kothare, SV; Shah, YD; Varughese, RT, 2022) |
| " We evaluated dosage and serum levels, efficacy, drug interactions, and adverse effects." | 1.72 | Initial Real-World Experience With Cenobamate in Adolescents and Adults: A Single Center Experience. ( Elliott, T; Gienapp, AJ; Ridley-Pryor, T; Wheless, JW, 2022) |
| "In about 30% of patients, the seizures are resistant to current treatments; so more effective treatments are urgently needed." | 1.72 | The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model. ( Bankstahl, J; Bankstahl, M; Bloms-Funke, P; Kneip, C; Löscher, W; Schröder, W, 2022) |
| "Patients with uncontrolled focal seizures taking stable doses of one to three ASMs were administered increasing doses of cenobamate (12." | 1.62 | Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications. ( Abou-Khalil, B; Aboumatar, S; Bhatia, P; Biton, V; Klein, P; Krauss, GL; Rosenfeld, WE; Sperling, MR; Vossler, DG; Wechsler, R, 2021) |
| "Patients with uncontrolled focal seizures taking stable doses of 1-3 antiseizure medications (ASMs) were administered increasing daily doses of cenobamate (12." | 1.62 | Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study. ( Abou-Khalil, B; Aboumatar, S; Bhatia, P; Biton, V; Ferrari, L; Grall, M; Klein, P; Krauss, GL; Rosenfeld, WE; Sperling, MR; Vossler, DG; Wechsler, R, 2021) |
| "Focal-onset or partial seizures are localized to a specific brain area or areas of the cerebral hemisphere." | 1.56 | Cenobamate for the treatment of focal epilepsy. ( Dhir, A, 2020) |
| "Increased neuronal excitability causes seizures with debilitating symptoms." | 1.48 | egl-4 modulates electroconvulsive seizure duration in C. elegans. ( Dawson-Scully, K; Jia, K; Kelly, SP; Minnerly, J; Risley, MG, 2018) |
| "Levobupivacaine (0." | 1.43 | Effectiveness of retigabine against levobupivacaine-induced central nervous system toxicity: a prospective, randomized animal study. ( Chen, Y; Cheng, Y; Duan, R; Li, H; Li, J; Yuan, J; Zhao, S, 2016) |
| "Retigabine reduced seizure frequency or severity for 24." | 1.43 | Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany. ( Elger, CE; Graf, W; Hamer, HM; Kasper, B; Kull, A; Kurth, C; Nass, RD; Rosenow, F; Steinhoff, BJ; Strzelczyk, A; Surges, R, 2016) |
| "Effects of RTG on KA-induced seizures of both strains of knock-in mice were assessed using seizure scores from a modified Racine's scale and compared with those of PB." | 1.43 | Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations. ( Deshimaru, M; Hirose, S; Ihara, Y; Ishii, A; Tomonoh, Y; Uchida, T; Zhang, B, 2016) |
| "Using patch-clamp recordings, seizure-like activity, tonic currents, and GABA-induced currents in hippocampal neurons were tested for their sensitivity toward retigabine, as were recombinant GABAA receptors expressed in tsA 201 cells." | 1.42 | The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors. ( Assadpour, E; Boehm, S; Gantumur, E; Hilber, K; Koenig, X; Kubista, H; Meyer, C; Treven, M, 2015) |
| "Chloroprocaine is a local ester anesthetic, producing excellent sensory block in clinical use." | 1.42 | Inhibition of Kv7/M Channel Currents by the Local Anesthetic Chloroprocaine. ( Cheng, Y; Jia, Q; Li, H; Zhang, F; Zhang, H; Zhao, S, 2015) |
| "Valproic acid (VPA) has been widely used for decades to treat epilepsy; however, its mechanism of action remains poorly understood." | 1.42 | M-current preservation contributes to anticonvulsant effects of valproic acid. ( Greene, DL; Hoshi, N; Kang, S; Kay, HY; Kosenko, A, 2015) |
| "There was no apparent change of the seizure initiation pattern when kainic acid was coadministrated with AM404, URB597 or AM251." | 1.42 | Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs. ( Aliev, R; Kitchigina, V; Shubina, L, 2015) |
| "Although inactive in acute seizure tests, repeated administration of SAR127303 delays the acquisition and decreases kindled seizures in mice, indicating that the drug slows down epileptogenesis, a finding deserving further investigation to evaluate the potential of MAGL inhibitors as antiepileptics." | 1.42 | Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. ( Arlt, H; Augé, F; Avenet, P; Beeské, S; Bergis, OE; Bert, L; Bertrand, T; Brittain, S; Didier, M; Escoubet, J; Even, L; Françon, D; George, P; Griebel, G; He, T; Houtmann, J; Jacquet, A; Leroy, T; Lopez-Grancha, M; Menet, V; Michot, N; Mikol, V; Pichat, P; Rak, A; Redon, N; Sun, F; Tolstykh, T; Vallée, F; Wiederschain, D; Yu, Q; Zhang, B, 2015) |
| " ABHD6 blockade retained its antiepileptic activity over chronic dosing and was not associated with psychomotor or cognitive effects." | 1.40 | ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice. ( Blankman, JL; Cao, JK; Cheah, CS; Cherry, AE; Cravatt, BF; Fung, S; Horne, EA; Hsu, KL; Li, W; Marrs, W; Naydenov, AV; Oakley, JC; Saporito, MS; Selley, DE; Stella, N; Swinney, K; Tu, S; Wen, A, 2014) |
| "Status epilepticus was induced by administration of KA either intraperitoneally (15 mg/kg) or by single intrahippocampal injection (1." | 1.40 | Retigabine calms seizure-induced behavior following status epilepticus. ( Ali, SS; Friedman, LK; Naseer, Z; Slomko, AM; Wongvravit, JP, 2014) |
| "At least, part of antiseizure effects of cannabinoid compounds is mediated through calcium (Ca(2+)) channels." | 1.38 | L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure. ( Ahmad-Molaei, L; Eslahkar, S; Mazar-Atabaki, A; Motiei-Langroudi, SM; Naderi, N; Ronaghi, A; Shirazi-zand, Z, 2012) |
| "Seizures were induced 30 min later using a chemoconvulsant (pentylenetetrazol, PTZ) model, which has been widely used to determine anticonvulsant efficacy of many other antiepileptic drugs in neonatal animals." | 1.38 | Anticonvulsant effect of retigabine during postnatal development in rats. ( Forcelli, PA; Gale, K; Kondratyev, A; Lakhkar, A; Soper, C, 2012) |
| "Only minor effects on seizure thresholds and seizure parameters without a clear dose-dependency were observed in fully kindled mice." | 1.37 | Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice. ( Potschka, H; Soerensen, J; Wendt, H; Wotjak, CT, 2011) |
| "Electroconvulsions were produced by means of an alternating current (ear-clip electrodes, fixed current intensity 35 mA, stimulus duration 0." | 1.35 | Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. ( Aziz Ahari, F; Motamedi, F; Naderi, N; Najarkolaei, AH; Shafaghi, B, 2008) |
| " The isobolographic analysis for parallel and nonparallel dose-response effects was used in the mouse maximal electroshock seizure (MES) model for evaluation of pharmacodynamic interaction." | 1.35 | Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. ( Czuczwar, SJ; Luszczki, JJ; Raszewski, G; Wu, JZ, 2009) |
| "In BFNC, seizures begin shortly after birth, and spontaneously remit in the first few months of life." | 1.34 | K+ M-current regulates the transition to seizures in immature and adult hippocampus. ( Johnson, BN; Qiu, C; Tallent, MK, 2007) |
| "Szt1 mouse seizure thresholds were significantly reduced relative to B6 littermates in the minimal clonic, minimal tonic hindlimb extension, and partial psychomotor seizure models." | 1.32 | Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. ( Frankel, WN; Otto, JF; White, HS; Wilcox, KS; Yang, Y, 2004) |
| "= 2." | 1.29 | D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. ( Bartsch, R; Engel, J; Hönack, D; Kutscher, B; Löscher, W; Polymeropoulos, EE; Rostock, A; Rundfeldt, C; Tober, C; White, HS; Wolf, HH, 1996) |
| "seizure severity, seizure duration, total duration of behavioural changes and afterdischarge duration." | 1.29 | D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. ( Bartsch, R; Rostock, A; Rundfeldt, C; Tober, C, 1996) |
| "The conclusion of this study was that a respiratory acidosis increased the central nervous system toxicity of local anaesthetics and that the underlying metabolic conditions modified this increase." | 1.25 | Central nervous system effects of local anaesthetic agents. ( Englesson, S; Matousek, M, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (21.62) | 18.7374 |
| 1990's | 3 (2.70) | 18.2507 |
| 2000's | 9 (8.11) | 29.6817 |
| 2010's | 38 (34.23) | 24.3611 |
| 2020's | 37 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Specchio, N | 1 |
| Pietrafusa, N | 1 |
| Vigevano, F | 1 |
| Rosenfeld, WE | 11 |
| Abou-Khalil, B | 3 |
| Aboumatar, S | 5 |
| Bhatia, P | 2 |
| Biton, V | 4 |
| Krauss, GL | 7 |
| Sperling, MR | 6 |
| Vossler, DG | 3 |
| Klein, P | 5 |
| Wechsler, R | 4 |
| Ferrari, L | 5 |
| Grall, M | 1 |
| Bloms-Funke, P | 1 |
| Bankstahl, M | 1 |
| Bankstahl, J | 1 |
| Kneip, C | 1 |
| Schröder, W | 1 |
| Löscher, W | 3 |
| Sander, JW | 1 |
| Halford, JJ | 2 |
| Steinhoff, BJ | 4 |
| Toledo, M | 1 |
| Privitera, M | 1 |
| Richy, FF | 1 |
| Schabert, VF | 1 |
| Hotta, N | 1 |
| Miyamoto, M | 1 |
| Suzuki, K | 1 |
| Lattanzi, S | 2 |
| Trinka, E | 2 |
| Zaccara, G | 2 |
| Striano, P | 2 |
| Russo, E | 1 |
| Del Giovane, C | 2 |
| Silvestrini, M | 2 |
| Brigo, F | 2 |
| Elliott, T | 1 |
| Ridley-Pryor, T | 1 |
| Gienapp, AJ | 1 |
| Wheless, JW | 1 |
| Varughese, RT | 1 |
| Shah, YD | 1 |
| Karkare, S | 1 |
| Kothare, SV | 1 |
| Kamin, M | 4 |
| Ben-Menachem, E | 1 |
| Brandt, C | 3 |
| García Morales, I | 1 |
| Santamarina, E | 1 |
| Serratosa, JM | 1 |
| Charlier, B | 1 |
| Coglianese, A | 1 |
| Operto, FF | 1 |
| Coppola, G | 1 |
| de Grazia, U | 1 |
| Menna, P | 1 |
| Filippelli, A | 1 |
| Dal Piaz, F | 1 |
| Izzo, V | 1 |
| Elakkary, S | 1 |
| Hagemann, A | 1 |
| Klimpel, D | 1 |
| Bien, CG | 1 |
| Vigil, FA | 1 |
| Belchior, H | 1 |
| Bugay, V | 1 |
| Bazaldua, II | 1 |
| Stoja, A | 1 |
| Dantas, DC | 1 |
| Chun, SH | 1 |
| Farmer, A | 1 |
| Bozdemir, E | 1 |
| Holstein, DM | 1 |
| Cavazos, JE | 1 |
| Lechleiter, JD | 1 |
| Brenner, R | 1 |
| Shapiro, MS | 1 |
| Rissardo, JP | 1 |
| Fornari Caprara, AL | 1 |
| Makridis, KL | 1 |
| Kaindl, AM | 1 |
| Brickel, N | 1 |
| Hewett, K | 1 |
| Rayner, K | 1 |
| McDonald, S | 1 |
| De'Ath, J | 1 |
| Daniluk, J | 2 |
| Joshi, K | 1 |
| Boll, MC | 1 |
| Tiamkao, S | 1 |
| Vorobyeva, O | 1 |
| Cooper, J | 1 |
| Dhir, A | 1 |
| Nisman, A | 2 |
| Pegan, A | 1 |
| Ursino, J | 1 |
| Gelfand, M | 1 |
| Borchert, L | 1 |
| Chung, SS | 2 |
| French, JA | 2 |
| Kowalski, J | 1 |
| Lee, SK | 2 |
| Maciejowski, M | 2 |
| Mizne, S | 1 |
| Kanyo, R | 1 |
| Wang, CK | 1 |
| Locskai, LF | 1 |
| Li, J | 2 |
| Allison, WT | 1 |
| Kurata, HT | 1 |
| Guignet, M | 1 |
| Campbell, A | 1 |
| White, HS | 3 |
| Sommerfeld-Klatta, K | 1 |
| Zielińska-Psuja, B | 1 |
| Karaźniewcz-Łada, M | 1 |
| Główka, FK | 1 |
| Elizebath, R | 1 |
| Zhang, E | 1 |
| Coe, P | 1 |
| Gutierrez, EG | 1 |
| Yang, J | 1 |
| Cutillo, G | 1 |
| Tolba, H | 1 |
| Hirsch, LJ | 1 |
| Zhang, L | 1 |
| Wang, J | 1 |
| Wang, C | 1 |
| Zhang, YM | 1 |
| Xu, HY | 1 |
| Hu, HN | 1 |
| Tian, FY | 1 |
| Chen, F | 2 |
| Liu, HN | 1 |
| Zhan, L | 2 |
| Pi, XP | 1 |
| Liu, J | 1 |
| Gao, ZB | 1 |
| Nan, FJ | 1 |
| Colangeli, R | 1 |
| Pierucci, M | 1 |
| Benigno, A | 1 |
| Campiani, G | 1 |
| Butini, S | 1 |
| Di Giovanni, G | 1 |
| Luszczki, JJ | 3 |
| Zagaja, M | 2 |
| Miziak, B | 2 |
| Kondrat-Wrobel, MW | 1 |
| Zaluska, K | 1 |
| Wroblewska-Luczka, P | 1 |
| Adamczuk, P | 1 |
| Czuczwar, SJ | 3 |
| Florek-Luszczki, M | 2 |
| Ostadhadi, S | 1 |
| Moradi, A | 1 |
| Zolfaghari, S | 1 |
| Nikoui, V | 1 |
| Dehpour, AR | 1 |
| Risley, MG | 1 |
| Kelly, SP | 1 |
| Minnerly, J | 1 |
| Jia, K | 1 |
| Dawson-Scully, K | 1 |
| Manville, RW | 1 |
| Abbott, GW | 1 |
| Sadek, B | 1 |
| Shehab, S | 1 |
| Więcek, M | 1 |
| Subramanian, D | 1 |
| Shafiullah, M | 1 |
| Kieć-Kononowicz, K | 1 |
| Adem, A | 1 |
| Zwierzyńska, E | 1 |
| Pietrzak, B | 1 |
| Slomko, AM | 1 |
| Naseer, Z | 1 |
| Ali, SS | 1 |
| Wongvravit, JP | 1 |
| Friedman, LK | 1 |
| Naydenov, AV | 1 |
| Horne, EA | 1 |
| Cheah, CS | 1 |
| Swinney, K | 1 |
| Hsu, KL | 1 |
| Cao, JK | 1 |
| Marrs, W | 1 |
| Blankman, JL | 1 |
| Tu, S | 1 |
| Cherry, AE | 1 |
| Fung, S | 1 |
| Wen, A | 1 |
| Li, W | 1 |
| Saporito, MS | 1 |
| Selley, DE | 1 |
| Cravatt, BF | 1 |
| Oakley, JC | 1 |
| Stella, N | 1 |
| Flemming, A | 1 |
| Zhou, P | 1 |
| Zhang, Y | 1 |
| Xu, H | 1 |
| Chen, X | 1 |
| Li, X | 1 |
| Pi, X | 1 |
| Wang, L | 1 |
| Nan, F | 1 |
| Gao, Z | 1 |
| Griebel, G | 1 |
| Pichat, P | 1 |
| Beeské, S | 1 |
| Leroy, T | 1 |
| Redon, N | 1 |
| Jacquet, A | 1 |
| Françon, D | 1 |
| Bert, L | 1 |
| Even, L | 1 |
| Lopez-Grancha, M | 1 |
| Tolstykh, T | 1 |
| Sun, F | 1 |
| Yu, Q | 1 |
| Brittain, S | 1 |
| Arlt, H | 1 |
| He, T | 1 |
| Zhang, B | 2 |
| Wiederschain, D | 1 |
| Bertrand, T | 1 |
| Houtmann, J | 1 |
| Rak, A | 1 |
| Vallée, F | 1 |
| Michot, N | 1 |
| Augé, F | 1 |
| Menet, V | 1 |
| Bergis, OE | 1 |
| George, P | 1 |
| Avenet, P | 1 |
| Mikol, V | 1 |
| Didier, M | 1 |
| Escoubet, J | 1 |
| Kumari, S | 1 |
| Mishra, CB | 1 |
| Tiwari, M | 1 |
| Shubina, L | 1 |
| Aliev, R | 1 |
| Kitchigina, V | 1 |
| Treven, M | 1 |
| Koenig, X | 1 |
| Assadpour, E | 1 |
| Gantumur, E | 1 |
| Meyer, C | 1 |
| Hilber, K | 1 |
| Boehm, S | 1 |
| Kubista, H | 1 |
| Zhang, F | 1 |
| Cheng, Y | 2 |
| Li, H | 2 |
| Jia, Q | 1 |
| Zhang, H | 1 |
| Zhao, S | 2 |
| Lerche, H | 1 |
| Lotay, N | 2 |
| DeRossett, S | 1 |
| Edwards, S | 1 |
| Chen, Y | 1 |
| Duan, R | 1 |
| Yuan, J | 1 |
| Kay, HY | 1 |
| Greene, DL | 1 |
| Kang, S | 1 |
| Kosenko, A | 1 |
| Hoshi, N | 1 |
| Nass, RD | 1 |
| Kurth, C | 1 |
| Kull, A | 1 |
| Graf, W | 1 |
| Kasper, B | 1 |
| Hamer, HM | 1 |
| Strzelczyk, A | 1 |
| Elger, CE | 1 |
| Surges, R | 1 |
| Rosenow, F | 1 |
| Ihara, Y | 1 |
| Tomonoh, Y | 1 |
| Deshimaru, M | 1 |
| Uchida, T | 1 |
| Ishii, A | 1 |
| Hirose, S | 1 |
| Lim, KS | 1 |
| White, R | 1 |
| Kwan, P | 1 |
| Mawasi, H | 1 |
| Bibi, D | 1 |
| Bialer, M | 2 |
| Smetana, KS | 1 |
| Cook, AM | 1 |
| Bastin, ML | 1 |
| Oyler, DR | 1 |
| Naderi, N | 3 |
| Aziz Ahari, F | 2 |
| Shafaghi, B | 1 |
| Najarkolaei, AH | 1 |
| Motamedi, F | 2 |
| Wu, JZ | 1 |
| Raszewski, G | 1 |
| Lu, X | 1 |
| Roberts, E | 1 |
| Xia, F | 1 |
| Sanchez-Alavez, M | 1 |
| Liu, T | 1 |
| Baldwin, R | 1 |
| Wu, S | 1 |
| Chang, J | 1 |
| Wasterlain, CG | 1 |
| Bartfai, T | 1 |
| Joosen, MJ | 1 |
| Smit, AB | 1 |
| van Helden, HP | 1 |
| Ahmad-Molaei, L | 2 |
| Wendt, H | 1 |
| Soerensen, J | 1 |
| Wotjak, CT | 1 |
| Potschka, H | 1 |
| Mazar-Atabaki, A | 1 |
| Ronaghi, A | 1 |
| Shirazi-zand, Z | 1 |
| Motiei-Langroudi, SM | 1 |
| Eslahkar, S | 1 |
| Deeks, ED | 1 |
| Hen, N | 1 |
| Yagen, B | 1 |
| Forcelli, PA | 1 |
| Soper, C | 1 |
| Lakhkar, A | 1 |
| Gale, K | 1 |
| Kondratyev, A | 1 |
| Hopkins, CR | 1 |
| Craig, D | 1 |
| Rice, S | 1 |
| Paton, F | 1 |
| Fox, D | 1 |
| Woolacott, N | 1 |
| Vilela, LR | 1 |
| Medeiros, DC | 1 |
| Rezende, GH | 1 |
| de Oliveira, AC | 1 |
| Moraes, MF | 1 |
| Moreira, FA | 1 |
| Amabile, CM | 1 |
| Vasudevan, A | 1 |
| HALPERN, BN | 1 |
| LEHMANN, A | 1 |
| DIAMOND, EF | 1 |
| NAKAMURA, K | 1 |
| NAKATSUJI, K | 1 |
| OHASHI, K | 1 |
| MASUDA, Y | 1 |
| FUJIMOTO, K | 1 |
| OSE, S | 1 |
| TSUTSUI, K | 1 |
| CARTER, CH | 1 |
| BERGER, FM | 2 |
| KLETZKIN, M | 1 |
| MARGOLIN, S | 1 |
| Otto, JF | 1 |
| Yang, Y | 1 |
| Frankel, WN | 1 |
| Wilcox, KS | 1 |
| Dekundy, A | 1 |
| Kaminski, RM | 1 |
| Zielinska, E | 1 |
| Turski, WA | 1 |
| Qiu, C | 1 |
| Johnson, BN | 1 |
| Tallent, MK | 1 |
| Grauer, E | 1 |
| Levy, A | 1 |
| Deshpande, LS | 1 |
| Nagarkatti, N | 1 |
| Sombati, S | 1 |
| DeLorenzo, RJ | 1 |
| Grabenstatter, HL | 1 |
| Dudek, FE | 1 |
| Takeda, M | 1 |
| Yoshimura, H | 1 |
| Tsukamoto, H | 1 |
| Casadio, S | 1 |
| Pala, G | 1 |
| Crescenzi, E | 1 |
| Marazzi-Uberti, E | 1 |
| Fresia, P | 1 |
| Macko, E | 1 |
| Wilfon, G | 1 |
| Greene, L | 1 |
| Bender, AD | 1 |
| Tedeschi, RE | 1 |
| Kornet, MJ | 1 |
| Kolasa, K | 1 |
| Kleinrok, Z | 1 |
| Rostock, A | 2 |
| Tober, C | 2 |
| Rundfeldt, C | 3 |
| Bartsch, R | 2 |
| Engel, J | 1 |
| Polymeropoulos, EE | 1 |
| Kutscher, B | 1 |
| Hönack, D | 1 |
| Wolf, HH | 1 |
| Armand, V | 1 |
| Heinemann, U | 1 |
| De Sarro, G | 1 |
| Di Paola, ED | 1 |
| Conte, G | 1 |
| Pasculli, MP | 1 |
| De Sarro, A | 1 |
| Van den Driessche, J | 1 |
| Le Clec'h, G | 1 |
| Patay, M | 1 |
| Englesson, S | 1 |
| Matousek, M | 1 |
| Mortensen, ML | 1 |
| Ferrini, R | 1 |
| Miragoli, G | 1 |
| Taccardi, B | 1 |
| Emmrich, P | 1 |
| Jüngst, BK | 1 |
| Dick, W | 1 |
| Wecker, L | 1 |
| Chiou, CY | 1 |
| Udall, ND | 1 |
| Nelson, WL | 1 |
| Sherwood, BE | 1 |
| Moffett, RB | 1 |
| Rudzik, AD | 1 |
| Gaultier, M | 2 |
| Frejaville, JP | 2 |
| Bismuth, C | 2 |
| Pebay-Peyroula, F | 2 |
| Andrews, TL | 1 |
| Miskus, RP | 1 |
| Ludwig, BJ | 1 |
| Powell, LS | 1 |
| Cittadini, D | 1 |
| De Cristofaro, D | 1 |
| Balestrieri, C | 1 |
| Cimino, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures[NCT02535091] | Phase 3 | 1,345 participants (Actual) | Interventional | 2016-08-03 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures[NCT03678753] | Phase 3 | 170 participants (Anticipated) | Interventional | 2018-09-21 | Recruiting | ||
| A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures[NCT01397968] | Phase 2 | 222 participants (Actual) | Interventional | 2011-07-06 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension[NCT01866111] | Phase 2 | 437 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy[NCT03934268] | 100 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy: A Randomized, add-on Placebo-controlled Clinical Trial[NCT03590197] | Phase 4 | 104 participants (Actual) | Interventional | 2018-08-06 | Completed | ||
| The Study of Pharmacokinetics of Levetiracetam in Patients Undergoing Intermittent Hemodialysis[NCT04511676] | 12 participants (Actual) | Observational | 2018-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Greater than or equal to 50% reduction in 28-day frequency of simple partial motor, and/or complex partial, and/or secondarily generalized tonic-clonic seizures during the 12 week treatment period relative to baseline. (NCT01397968)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| YKP3089 | 57 |
| Placebo | 24 |
Percent change in 28-day frequency of simple partial motor, and/or complex partial, and/or secondarily generalized tonic-clonic seizures during the 12 week treatment period relative to baseline (NCT01397968)
Timeframe: assessed per 28 days during 12 week period; change from baseline and 12 weeks reported
| Intervention | percent seizure reduction (Median) |
|---|---|
| YKP3089 | 55.6 |
| Placebo | 21.5 |
Percentage of patients achieving a 50% or more reduction from baseline in partial seizure frequency during the double-blind treatment period (NCT01866111)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 23 |
| Cenobamate 100 mg/Day | 44 |
| Cenobamate 200 mg/Day | 63 |
| Cenobamate 400 mg/Day | 67 |
Percent change in complex partial and/or secondarily generalized and/or simple partial motor seizure frequency per 28 days (average 28-day seizure rate) in each treatment group during the double-blind period relative to the pretreatment baseline. (NCT01866111)
Timeframe: baseline and 18 weeks
| Intervention | percent change (Median) |
|---|---|
| Placebo | -24.0 |
| Cenobamate 100 mg/Day | -35.5 |
| Cenobamate 200 mg/Day | -55.0 |
| Cenobamate 400 mg/Day | -55.0 |
20 reviews available for carbamates and Seizures
| Article | Year |
|---|---|
Is Cenobamate the Breakthrough We Have Been Wishing for?
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy; Humans; Seizures; Tetrazoles | 2021 |
Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; H | 2022 |
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Dibenzazepines; Double-Blind Method; Drug Therapy | 2022 |
Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature.
Topics: Animals; Carbamates; Chlorophenols; Drug Resistant Epilepsy; Seizures; Tetrazoles; United States | 2023 |
Real-world experience with cenobamate: A systematic review and meta-analysis.
Topics: Adult; Anticonvulsants; Carbamates; Child; Drug Resistant Epilepsy; Epilepsies, Partial; Humans; Sei | 2023 |
Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Drug Therapy, Combination; Epilepsy; Humans; Rand | 2020 |
Cenobamate (Xcopri) for focal seizures.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Clinical Trials as Topic; Drug Therapy, Combination; Hum | 2020 |
[Cenobamate-a new perspective for epilepsy treatment].
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy; Humans; Seizures; Tetrazoles | 2021 |
Cenobamate (XCOPRI): Can preclinical and clinical evidence provide insight into its mechanism of action?
Topics: Animals; Anticonvulsants; Carbamates; Chlorophenols; Drug Evaluation, Preclinical; Humans; Randomize | 2020 |
New Methods Used in Pharmacokinetics and Therapeutic Monitoring of the First and Newer Generations of Antiepileptic Drugs (AEDs).
Topics: Anticonvulsants; Carbamates; Chlorophenols; Drug Monitoring; Humans; Seizures; Tetrazoles | 2020 |
Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP prevention.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Epilepsy, Tonic-Clonic; Humans; Seizures; Sudden Unexpec | 2021 |
Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Dizziness; Dose-Response Relationship, Drug; Drug Resist | 2021 |
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.
Topics: Animals; Anticonvulsants; Bromides; Carbamates; Chlorophenols; Drug Therapy, Combination; Epilepsy; | 2021 |
[Retigabine - a new antiepileptic drug with a different mechanism of action].
Topics: Adult; Anticonvulsants; Carbamates; Drug Interactions; GABA Modulators; Humans; Lamotrigine; Membran | 2013 |
Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy.
Topics: Acetamides; Acute Kidney Injury; Amines; Anticonvulsants; Carbamates; Critical Illness; Cyclohexanec | 2016 |
Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.
Topics: Anticonvulsants; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic | 2011 |
ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine).
Topics: Anticonvulsants; Carbamates; Epilepsy; Humans; KCNQ Potassium Channels; Phenylenediamines; Potassium | 2012 |
Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Cost-Benefit Analysis; Decision Support Techniques; | 2013 |
Ezogabine: a novel antiepileptic for adjunctive treatment of partial-onset seizures.
Topics: Animals; Anticonvulsants; Carbamates; Drug Therapy, Combination; Humans; Phenylenediamines; Randomiz | 2013 |
Management of acute childhood poisonings caused by selected insecticides and herbicides.
Topics: Absorption; Adolescent; Animals; Anticonvulsants; Atropine; Carbamates; Central Nervous System; Chil | 1986 |
11 trials available for carbamates and Seizures
| Article | Year |
|---|---|
Long-term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; H | 2022 |
Onset of efficacy and adverse events during Cenobamate titration period.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Drug Therapy, Combination; Epilepsies, Partial; H | 2022 |
Post hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: Adjunctive cenobamate dose and seizure reduction by baseline seizure frequency.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; Humans; | 2022 |
Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events.
Topics: Adult; Anticonvulsants; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Therapy, | 2020 |
Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Thera | 2020 |
Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Co | 2020 |
Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Chlorophenols; Humans; Quality of Life; Seizures; Te | 2021 |
Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: A post-hoc analysis of a randomized clinical study.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; E | 2021 |
Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; Humans; | 2021 |
Efficacy and safety of ezogabine/retigabine as adjunctive therapy to specified single antiepileptic medications in an open-label study of adults with partial-onset seizures.
Topics: Aged; Anticonvulsants; Carbamates; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, Co | 2015 |
Efficacy and safety of retigabine/ezogabine as adjunctive therapy in adult Asian patients with drug-resistant partial-onset seizures: A randomized, placebo-controlled Phase III study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Double-Blind Method; Drug Resistant Epilepsy; | 2016 |
80 other studies available for carbamates and Seizures
| Article | Year |
|---|---|
Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; Humans; | 2021 |
Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; H | 2021 |
The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model.
Topics: Animals; Anticonvulsants; Carbamates; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Elect | 2022 |
Lamotrigine and retigabine increase motor threshold in transcranial magnetic stimulation at the dose required to produce an antiepileptic effect against maximal electroshock-induced seizure in rats.
Topics: Animals; Anticonvulsants; Carbamates; Electroshock; Evoked Potentials, Motor; Lamotrigine; Male; Phe | 2022 |
Initial Real-World Experience With Cenobamate in Adolescents and Adults: A Single Center Experience.
Topics: Adolescent; Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug-Related Side Effec | 2022 |
Adjunctive use of cenobamate for pediatric refractory focal-onset epilepsy: A single-center retrospective study.
Topics: Adolescent; Adult; Anticonvulsants; Carbamates; Child; Chlorophenols; Drug Resistant Epilepsy; Epile | 2022 |
Efficacy of cenobamate by focal seizure subtypes: Post-hoc analysis of a phase 3, multicenter, open-label study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Caffeine; Carbamates; Chlorophenols; Double-Blind Method; | 2022 |
Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: Post hoc analysis of a phase 3, multicenter, open-label study.
Topics: Anticonvulsants; Carbamates; Chlorophenols; Double-Blind Method; Drug Therapy, Combination; Epilepsy | 2022 |
Development and Validation of a UHPLC-MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples.
Topics: Carbamates; Chlorophenols; Chromatography, High Pressure Liquid; Humans; Seizures; Tandem Mass Spect | 2022 |
A retrospective non-interventional study evaluating the pharmacokinetic interactions between cenobamate and clobazam.
Topics: Adult; Anticonvulsants; Carbamates; Clobazam; Humans; Retrospective Studies; Seizures | 2023 |
Acute Treatment with the M-Channel (K
Topics: Animals; Brain Injuries, Traumatic; Carbamates; Epilepsy, Post-Traumatic; Mice; Seizures | 2023 |
Cenobamate for the treatment of focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamates; Chlorophenols; Epilepsies, Partial; Humans; Seizures; Tetrazoles | 2020 |
An Ex Vivo Evaluation of Cenobamate Administered via Enteral Tubes.
Topics: Administration, Oral; Anticonvulsants; Carbamates; Chlorophenols; Enteral Nutrition; Humans; Seizure | 2020 |
Functional and behavioral signatures of Kv7 activator drug subtypes.
Topics: Anilides; Animals; Animals, Genetically Modified; Anticonvulsants; Bridged Bicyclo Compounds; Calciu | 2020 |
Discovery of HN37 as a Potent and Chemically Stable Antiepileptic Drug Candidate.
Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Dogs; Drug Design; Drug Evaluation, Pr | 2021 |
The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity.
Topics: Amidohydrolases; Animals; Benzamides; Cannabinoids; Carbamates; Dentate Gyrus; Long-Term Potentiatio | 2017 |
Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis.
Topics: Acetamides; Animals; Anticonvulsants; Brain; Carbamates; Dose-Response Relationship, Drug; Drug Comb | 2018 |
Cromakalim, a Potassium Channel Opener, Ameliorates the Organophosphate and Carbamate-Induced Seizure in Mice.
Topics: Animals; Anticonvulsants; Carbamates; Cromakalim; Dichlorvos; Dose-Response Relationship, Drug; Glyb | 2018 |
egl-4 modulates electroconvulsive seizure duration in C. elegans.
Topics: Animals; Anticonvulsants; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Carbamates; Cycli | 2018 |
Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket.
Topics: Animals; Anticonvulsants; Carbamates; Drug Synergism; Hemiterpenes; KCNQ Potassium Channels; Mallotu | 2018 |
Anticonvulsant properties of histamine H3 receptor ligands belonging to N-substituted carbamates of imidazopropanol.
Topics: 1-Propanol; Animals; Anticonvulsants; Carbamates; Electroshock; Histamine Agonists; Histamine Antago | 2013 |
Retigabine calms seizure-induced behavior following status epilepticus.
Topics: Animals; Anticonvulsants; Anxiety; Behavior, Animal; Carbamates; Convulsants; Hippocampus; Hyperkine | 2014 |
ABHD6 blockade exerts antiepileptic activity in PTZ-induced seizures and in spontaneous seizures in R6/2 mice.
Topics: Animals; Anticonvulsants; Behavior, Animal; Brain; Carbamates; Male; Mice; Mice, Knockout; Monoacylg | 2014 |
Epilepsy: endocannabinoid metabolism offers handle to dampen down excitability.
Topics: Animals; Anticonvulsants; Brain; Carbamates; Male; Monoacylglycerol Lipases; Seizures | 2014 |
P-retigabine: an N-propargyled retigabine with improved brain distribution and enhanced antiepileptic activity.
Topics: Action Potentials; Animals; Anticonvulsants; Carbamates; Cells, Cultured; CHO Cells; Cricetulus; Dis | 2015 |
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents.
Topics: Acetylcholine; Administration, Oral; Analgesics; Animals; Arachidonic Acids; Binding Sites; Brain; C | 2015 |
Design, synthesis and pharmacological evaluation of N-[4-(4-(alkyl/aryl/heteroaryl)-piperazin-1-yl)-phenyl]-carbamic acid ethyl ester derivatives as novel anticonvulsant agents.
Topics: Animals; Anticonvulsants; Carbamates; Drug Design; Electroshock; Epilepsy; Mice; Pentylenetetrazole; | 2015 |
Attenuation of kainic acid-induced status epilepticus by inhibition of endocannabinoid transport and degradation in guinea pigs.
Topics: Amidohydrolases; Animals; Anticonvulsants; Arachidonic Acids; Benzamides; Biological Transport; Brai | 2015 |
The anticonvulsant retigabine is a subtype selective modulator of GABAA receptors.
Topics: Animals; Anticonvulsants; Carbamates; Cells, Cultured; Dose-Response Relationship, Drug; GABA Modula | 2015 |
Synergistic Interaction of Retigabine with Levetiracetam in the Mouse Maximal Electroshock-Induced Seizure Model: A Type II Isobolographic Analysis.
Topics: Animals; Brain; Carbamates; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combinat | 2015 |
Inhibition of Kv7/M Channel Currents by the Local Anesthetic Chloroprocaine.
Topics: Anesthetics, Local; Animals; Carbamates; Dose-Response Relationship, Drug; Ganglia, Spinal; HEK293 C | 2015 |
Effectiveness of retigabine against levobupivacaine-induced central nervous system toxicity: a prospective, randomized animal study.
Topics: Animals; Anticonvulsants; Bupivacaine; Carbamates; Central Nervous System; KCNQ2 Potassium Channel; | 2016 |
M-current preservation contributes to anticonvulsant effects of valproic acid.
Topics: A Kinase Anchor Proteins; Action Potentials; Animals; Anthracenes; Anticonvulsants; Carbamates; Cell | 2015 |
Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamates; Child; Death, Sudden, Cardiac; Drug Resistant | 2016 |
Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.
Topics: Animals; Carbamates; Gene Knock-In Techniques; Humans; Ion Channel Gating; Kainic Acid; KCNQ2 Potass | 2016 |
Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
Topics: Animals; Anticonvulsants; Blood-Brain Barrier; Carbamates; Electroshock; Imidazoles; Male; Mice; Rat | 2016 |
Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice.
Topics: Amidohydrolases; Animals; Anticonvulsants; Arachidonic Acids; Benzamides; Benzoxazines; Cannabinoid | 2008 |
Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model.
Topics: Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Brain; Carbamates; Carbamazepine; Di | 2009 |
GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models.
Topics: Allosteric Regulation; Animals; Anticonvulsants; Carbamates; Cell Line; Dipeptides; Disease Models, | 2010 |
Treatment efficacy in a soman-poisoned guinea pig model: added value of physostigmine?
Topics: Animals; Atropine; Brain; Carbamates; Chemical Warfare Agents; Dose-Response Relationship, Drug; Dru | 2011 |
Modulation of anticonvulsant effects of cannabinoid compounds by GABA-A receptor agonist in acute pentylenetetrazole model of seizure in rat.
Topics: Animals; Anticonvulsants; Benzamides; Benzoxazines; Biphenyl Compounds; Brain; Calcium Channel Block | 2011 |
Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice.
Topics: Amidohydrolases; Amygdala; Animals; Benzamides; Benzoxazines; Carbamates; Disease Models, Animal; Ep | 2011 |
L-type calcium channel mediates anticonvulsant effect of cannabinoids in acute and chronic murine models of seizure.
Topics: Acute Disease; Animals; Anticonvulsants; Benzamides; Benzoxazines; Calcium Channels, L-Type; Cannabi | 2012 |
Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates.
Topics: Animals; Anticonvulsants; Carbamates; Male; Mice; Neurotoxicity Syndromes; Rats; Rats, Sprague-Dawle | 2012 |
Anticonvulsant effect of retigabine during postnatal development in rats.
Topics: Aging; Animals; Animals, Newborn; Anticonvulsants; Carbamates; Convulsants; Dose-Response Relationsh | 2012 |
Treating seizures. Achievable control.
Topics: Anticonvulsants; Carbamates; Electric Stimulation Therapy; Humans; Neurosurgical Procedures; Phenyle | 2012 |
Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats.
Topics: Animals; Benzamides; Benzoxazines; Cannabinoids; Carbamates; Convulsants; Disease Models, Animal; El | 2013 |
[Protective effect of 3-methyl-1-pentyne-3-ol carbamate against the audiogenic convulsive fit].
Topics: Carbamates; Hypnotics and Sedatives; Seizures; Sound | 1956 |
An evaluation of AC-601, a new carbamate anticonvulsant, in the therapy of childhood convulsive disorders.
Topics: Anti-Anxiety Agents; Anticonvulsants; Carbamates; Epilepsy; Esters; Humans; Seizures | 1963 |
THE ANTICONVULSANT ACTIVITY OF ETHYL ALPHA-PHENYLBUTYROYL ALLOPHANATE (P-5257).
Topics: Anticonvulsants; Barbiturates; Carbamates; Central Nervous System; Mice; Pentylenetetrazole; Pharmac | 1963 |
EVALUATION OF 2-HYDROXYETHYL-N-BENZYLCARBAMATE IN EPILEPSY.
Topics: Adolescent; Anticonvulsants; Biomedical Research; Carbamates; Child; Epilepsy; Epilepsy, Absence; Ep | 1964 |
PHARMACOLOGIC PROPERTIES OF A NEW TRANQUILIZING AGENT, 2-METHYL-2-PROPYLTRIMETHYLENE BUTYLCARBAMATE CARBAMATE (TYBAMATE).
Topics: Blood Pressure; Blood Pressure Determination; Carbamates; Cats; Dogs; Electroencephalography; Hypnot | 1964 |
Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel.
Topics: Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Electroshock; Female; Genetic Predispo | 2004 |
NMDA antagonists exert distinct effects in experimental organophosphate or carbamate poisoning in mice.
Topics: Animals; Atropine; Carbamates; Cholinesterase Inhibitors; Dichlorvos; Dizocilpine Maleate; Dose-Resp | 2007 |
K+ M-current regulates the transition to seizures in immature and adult hippocampus.
Topics: Action Potentials; Animals; Anticonvulsants; Carbamates; Disease Models, Animal; Epilepsy, Benign Ne | 2007 |
Oxotremorine-induced hypothermia as a method for evaluating long-term neuronal changes following poisoning by cholinesterase inhibitors in rats.
Topics: Aldicarb; Animals; Body Temperature; Carbamates; Central Nervous System; Cholinesterase Inhibitors; | 2007 |
The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons.
Topics: Animals; Anticonvulsants; Carbamates; Cells, Cultured; Data Interpretation, Statistical; Dose-Respon | 2008 |
A new potential AED, carisbamate, substantially reduces spontaneous motor seizures in rats with kainate-induced epilepsy.
Topics: Analysis of Variance; Animals; Anticonvulsants; Carbamates; Cross-Over Studies; Disease Models, Anim | 2008 |
[Metabolism of drugs. LIV. On the pharmacological action of carbamate N-glucuronides].
Topics: Animals; Carbamates; Coma; Glucuronates; Male; Meprobamate; Mice; Pentobarbital; Rats; Seizures; Ure | 1966 |
Synthesis and pharmacological properties of acylphenol-ethers.
Topics: Amphetamine; Animals; Anticonvulsants; Carbamates; Central Nervous System; Ethers, Cyclic; Hydroxypr | 1966 |
Pharmacological properties of the isopropyl ester of o-sulfamoyl-benzoic acid.
Topics: Animals; Behavior, Animal; Benzoates; Carbamates; Carisoprodol; Chlordiazepoxide; Chlormezanone; Chl | 1967 |
Synthesis of phenylurethans of 1,2-dialkyl-4-pyrazolidinols as anticonvulsant agents.
Topics: Animals; Anticonvulsants; Carbamates; Drug Evaluation, Preclinical; Male; Mice; Nervous System; Phen | 1980 |
[Central effect of various new carbamide and succinimide derivatives of benzoxazolone-2].
Topics: Animals; Anticonvulsants; Benzoxazoles; Brain; Carbamates; Central Nervous System Depressants; Chemi | 1981 |
D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.
Topics: Administration, Oral; Animals; Anticonvulsants; Behavior, Animal; Bicuculline; Carbamates; Dyskinesi | 1996 |
D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures.
Topics: Animals; Anticonvulsants; Carbamates; Female; Kindling, Neurologic; Phenylenediamines; Rats; Rats, W | 1996 |
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bicuculline; Carbamates; Convulsants; Electrophysiology; | 1999 |
Influence of retigabine on the anticonvulsant activity of some antiepileptic drugs against audiogenic seizures in DBA/2 mice.
Topics: Animals; Anticonvulsants; Body Temperature; Carbamates; Dose-Response Relationship, Drug; Drug Syner | 2001 |
[Heart noradrenaline and dopamine during acute poisoning of rat by an anticholinesterasic pesticide: parathion].
Topics: Acetylcholine; Animals; Atropine; Carbamates; Diazepam; Dopamine; Female; Heart; Heart Rate; Myocard | 1975 |
Central nervous system effects of local anaesthetic agents.
Topics: Acid-Base Equilibrium; Acidosis, Respiratory; Allyl Compounds; Amines; Anesthetics, Local; Anilides; | 1975 |
Neuro-pharmacological studies on SB 5833, a new psychotherapeutic agent of the benzodiazepine class.
Topics: Aggression; Amphetamine; Animals; Anti-Anxiety Agents; Avoidance Learning; Carbamates; Chlordiazepox | 1974 |
[Possible applications of complete relaxation in pediatric intensive care].
Topics: Acid-Base Equilibrium; Acidosis, Respiratory; Anticonvulsants; Carbamates; Child; Child, Preschool; | 1971 |
Central cholinomimetic actions of 3, 3-dimethyl-1-butanol carbamate.
Topics: Acetylcholine; Animals; Atropine; Brain; Carbamates; Carbon Isotopes; Dose-Response Relationship, Dr | 1973 |
The toxicity of the molluscicides metaldehyde and methiocarb to dogs.
Topics: Acetaldehyde; Animals; Atropine; Carbamates; Dog Diseases; Dogs; Gluconates; Glucose; Hyperemia; Kid | 1973 |
Centrally acting muscle relaxants. Isomeric 9,10-dihydroxy-1,2,3,4,4a,9,10,10a(trans-4a,10a)-octahydrophenanthrenes and their carbamate esters.
Topics: Animals; Carbamates; Electroshock; Male; Mass Spectrometry; Mice; Molecular Conformation; Motor Acti | 1974 |
Central nervous system depressants. 10. 1-Carbamoylbenzodiazepines.
Topics: Animals; Behavior, Animal; Benzazepines; Carbamates; Central Nervous System; Depression, Chemical; D | 1972 |
[Analysis of histories of cases of hypoxia during acute poisoning seen at the Hôpital Fernand-Widal].
Topics: Antidepressive Agents; Barbiturates; Blood Circulation; Carbamates; Carbon Monoxide Poisoning; Franc | 1970 |
[Analysis of the records of hypoxia cases cropping up at the time of acute poisoning at the Fernand Widal Hospital].
Topics: Barbiturates; Carbamates; Humans; Hypoxia; Medical Records; Paris; Phenothiazines; Poisoning; Seizur | 1970 |
Tetraethylammonium chloride as an antidote for certain insecticides in mice.
Topics: Animals; Antidotes; Atropine; Carbamates; Insecticides; Mice; Nicotine; Parathion; Seizures; Tetraet | 1968 |
Carbamate derivatives related to meprobamate.
Topics: Animals; Carbamates; Central Nervous System; Chemical Phenomena; Chemistry; Meprobamate; Mice; Muscl | 1969 |
Carbamylaspartate, a new agent against acute ammonia intoxication.
Topics: Ammonia; Animals; Aspartic Acid; Carbamates; Male; Mortality; Rats; Seizures | 1966 |